- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Announcement
Robotics and functional electrical stimulation for stroke rehabilitation
Robotic assisted rehabilitation (RAR) and functional electrostimulation (FES) can, among others, be used as a supplement to conventional rehabili-tation in post-stroke patients. The use of RAR could have the advantage of allowing more intensive and frequent therapy (by increasing the motiva-tion to train), which at the same time reduces the effort of the physiotherapist. FES is a targeted application of electrical stimulation inducing muscle contractions supporting motor activities. The electrical stimulation takes place during a functional movement and may, inter alia, strengthen the muscle and improve blood circulation or blood flow.
This report aimed at evaluating the additional clinical benefit of RAR and FES. Systematic reviews of effectiveness and safety were conducted in cooperation with a working group (ReMoS/ Rehabilitation of Mobility after Stroke - AG) of the Association of the Scientific Medical Societies in Germany (AWMF)
Publication: LBI-HTA Project Report No.: 128: https://eprints.aihta.at/1302
Contact: Gregor Goetz
Announcement
Horizon Scanning in Oncology - Fact Sheets
Fact Sheet No. 41 (February 2021)
Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)
Fact Sheet No. 42 (February 2021)
Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)
Fact Sheet No. 43 (February 2021)
Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Managed Entry Agreements (MEA), anwendungsbegleitende Datenerhebung, Coverage with Evidence Development (CED) – Erkenntnisgewinn oder Zeitvertreib ?
- Selektive Interne Radiotherapie (SIRT) zur Behandlung vom inoperablem hepatozellulärem Karzinom im frühen, mittleren oder fortgeschrittenen Stadium
- Chirurgische Verfahren bei gutartiger Prostatahyperplasie (BPH)
- Künstliche Intelligenz bei Mammographien und zur Analyse von Thorax-CT-Bildern
- Implantierbare Herzmonitore zur Erkennung von Vorhofflimmern nach kryptogenem Schlaganfall
- Termine
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v12 March 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our three new HSO Fact Sheets.
Fact Sheet No. 38 (January 2021)
Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)
Fact Sheet No. 39 (January 2021)
Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 40 (January2021)
Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v11 February 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
Newsletter
Note: this content is only available in German.
Inhalt
- Evidenz vs. politischer Aktionismus: REGN-COV2 und Bamlanivimab
- Wirksamkeit, Sicherheit und Vorhersagegenauigkeit von Bluttests für Frauen mit Verdacht auf Präeklampsie
- Chondroitinsulfat bei Osteoarthrose
- Robotik und funktionelle Elektrostimulation als Hilfsmittel innerhalb der Schlaganfallrehabilitation.
- Intrakoronare Lithotripsie zur Behandlung koronarer Herzkrankheit
- Termine
- Themen-Vorschau
Announcement
Annual Report 2020 online
We are pleased to release the first AIHTA Annual Report 2020.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Forschung zu psychischer Gesundheit braucht mehr Aufmerksamkeit und Strategie
- Molekulare Tests bei Verdacht einer Infektion mit COVID-19: Testgenauigkeit
- Nutzenbewertung von digitalen Gesundheitsanwendungen
- Klinische Evidenz von Lungenkrebs-Screening bei Risikogruppen (Teil 1)
- Kosteneffektivität von Lungenkrebs-Screening mittels Niedrigdosis-Computertomographie bei Risikogruppen (Teil 2)
- Termine
- Themen-Vorschau
Announcement
Covid-19: HSS/ Horizon Scanning Living Document (v10 January 2021)
The establishment of a HSS/ Horizon Scanning System for Covid19 interventions has the intentions of informing health policy makers at an early stage which interventions (vaccinations and drugs) are currently undergoing clinical trials and to monitor them over the next few months in order to support evidence-based purchasing if necessary. The products are monitored with regard to the status of the clinical studies up to approval and finally evaluated for their benefit and harm.
All work steps are conducted in close international (European) cooperation.
Publications:
- Policy Brief No. 002: http://eprints.aihta.at/1234/
Contact: Claudia Wild
